All payments made in the preview are in test mode. Read more
Preview
Regulation

Tandem Mobi gains FDA clearance for a tubeless option

A new cartridge and infusion set retain the existing pump, with a full US launch planned for the first half of 2027.

MedTechPost.com Newsroom
Tandem Mobi gains FDA clearance for a tubeless option
Illustration: AI-generated

Tandem Diabetes Care has reported FDA clearance for a tubeless option for Tandem Mobi. A new cartridge and infusion set convert the existing pump into a wearable tubeless system.

Tubed use remains possible. The manufacturer describes up to seven days of wear with Control-IQ+ automated insulin delivery. Full US commercial launch is planned for the first half of 2027. Existing Mobi pumps are compatible, and in-warranty customers do not need a replacement pump, according to the company.

Context and evidence

The sets and cartridges are planned for pharmacy-only access for people with applicable insurance benefits. This concerns both hardware and a defined access channel. The planned launch date is separate from the clearance already granted; the source contains no independent head-to-head comparison with other tubeless systems.

What it means

The option adds a new wear configuration to an existing platform. Actual access will depend on launch, insurance benefits and medical suitability, not clearance alone.

Primary source: Original announcement. This report is based on company statements, not an independent clinical assessment.

Author
MedTechPost.com Newsroom
Source-based medical technology reporting with AI assistance and clear editorial context.

More from Regulation